Astellas Pharma Hits Day High with 5.5% Surge in Stock Price

Astellas Pharma, Inc. has experienced a significant uptick in its stock performance, gaining 5.5% on April 1, 2026. The stock reached an intraday high of JPY 2,657.50, reflecting strong market activity. Over the past year, Astellas has outperformed the Japan Nikkei 225, generating a remarkable return of 81.9% compared to the index's 50.85%. The company's financial metrics indicate robust operational efficiency, highlighted by a return on equity (ROE) of 7.74% and a healthy EBIT to interest ratio of 42.73. Astellas reported a notable growth in net sales of 10.4%, contributing to its strong financial standing. The operating cash flow reached its highest at JPY 463,969 million, and the return on capital employed (ROCE) stood at 19.83%. With a market capitalization of JPY 4,060,884 million, Astellas Pharma continues to demonstrate its position as a leading player in the pharmaceuticals and biotechnology sector. The stock's performance metrics, including a price-to-book ratio of 2.52, further underscore its competitive standing in the market.